FGI-103
 | |
| Systematic (IUPAC) name | |
|---|---|
|
2-[(E)-2-(5-carbamimidoyl-1-benzofuran-2-yl)ethenyl]-3H-benzimidazole-5-carboximidamide | |
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Number |
907169-69-1  |
| PubChem | CID 5477931 |
| ChemSpider | 4585571 |
| Chemical data | |
| Formula | C19H16N6O |
| Molar mass | 344.369 |
| |
| |
FGI-103 is an antiviral drug developed as a potential treatment for the filoviruses Ebola virus and Marburg virus. In tests on mice FGI-103 was effective against both Ebola and Marburg viruses when administered up to 48 hours after infection. The mechanism of action of FGI-103 has however not yet been established, as it was found not to be acting by any of the known mechanisms used by similar antiviral drugs.[1][2]
See also
References
- ↑ Warren, T. K.; Warfield, K. L.; Wells, J.; Enterlein, S.; Smith, M.; Ruthel, G.; Yunus, A. S.; Kinch, M. S.; Goldblatt, M.; Aman, M. J.; Bavari, S. (2010). "Antiviral Activity of a Small-Molecule Inhibitor of Filovirus Infection". Antimicrobial Agents and Chemotherapy 54 (5): 2152–9. doi:10.1128/AAC.01315-09. PMC 2863630. PMID 20211898.
- ↑ Bradfute, S. B.; Warfield, K. L.; Bray, M. (2012). "Mouse Models for Filovirus Infections". Viruses 4 (12): 1477–1508. doi:10.3390/v4091477.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.